Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SRPT

Sarepta Therapeutics Inc

Feb 13 • 04:00PM ET

17.79

+0.39 2.24 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN ALNY IONS PFE PTCT EXEL PRTA BLUE RDUS

| Held by: IJR VTI XBI FBT VB VBK VXF SPSM FXH IBB

Index	-	P/E	-	EPS (ttm)	-2.89	Insider Own	5.88%	Shs Outstand	104.77M	Perf Week	-3.84%
Market Cap	1.86B	Forward P/E	9.22	EPS next Y	1.93	Insider Trans	-0.21%	Shs Float	98.62M	Perf Month	-21.97%
Enterprise Value	2.26B	PEG	1.64	EPS next Q	-1.20	Inst Own	85.86%	Short Float	22.53%	Perf Quarter	-1.17%
Income	-271.51M	P/S	0.77	EPS this Y	-324.40%	Inst Trans	0.47%	Short Ratio	7.04	Perf Half Y	-12.36%
Sales	2.41B	P/B	1.41	EPS next Y	139.42%	ROA	-7.66%	Short Interest	22.22M	Perf YTD	-17.33%
Book/sh	12.60	P/C	2.19	EPS next 5Y	5.64%	ROE	-21.37%	52W High	111.21 -84.00%	Perf Year	-83.75%
Cash/sh	8.12	P/FCF	-	EPS past 3/5Y	- -	ROIC	-10.56%	52W Low	10.41 70.81%	Perf 3Y	-85.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.42% 37.94%	Gross Margin	74.19%	Volatility	4.38% 6.33%	Perf 5Y	-80.47%
Dividend TTM	-	EV/Sales	0.94	EPS Y/Y TTM	-311.26%	Oper. Margin	-3.56%	ATR (14)	1.24	Perf 10Y	44.05%
Dividend Ex-Date	-	Quick Ratio	1.78	Sales Y/Y TTM	47.15%	Profit Margin	-11.25%	RSI (14)	38.08	Recom	2.77
Dividend Gr. 3/5Y	- -	Current Ratio	2.95	EPS Q/Q	-630.03%	SMA20	-11.13%	Beta	0.42	Target Price	21.43
Payout	0.00%	Debt/Eq	0.95	Sales Q/Q	-14.52%	SMA50	-15.89%	Rel Volume	0.49	Prev Close	17.40
Employees	1372	LT Debt/Eq	0.95	Earnings	Nov 03 AMC	SMA200	-23.08%	Avg Volume	3.16M	Price	17.79
IPO	Jun 04, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	-147.59% 18.94%	Trades		Volume	1,554,548	Change	2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Equal Weight	$20
Dec-09-25	Initiated	Wedbush	Outperform	$32
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform	$26
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform	$37
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral	$24
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight	$22
Jul-29-25	Reiterated	H.C. Wainwright	Sell	$5
Jul-29-25	Initiated	Bernstein	Mkt Perform	$13
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight	$10
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell	$7
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight	$18
Jul-21-25	Downgrade	UBS	Buy → Neutral	$12
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral	$14
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform	$10
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold	$9
Jul-18-25	Downgrade	Needham	Buy → Hold

Show Previous Ratings

Feb-11-26 08:30AM	Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results (Business Wire)
Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com) +8.63%
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -13.68%
Jan-31-26 12:02AM	Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags (MarketBeat)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
06:45AM	Loading…
06:45AM	Sarepta eyes Elevidys sales comeback with positive Phase III data (Clinical Trials Arena)
Jan-26-26 04:17PM	Sarepta Pops On Elevidys Data; But Will It Save The Embattled Gene Therapy? (Investor's Business Daily) +7.90%
02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
01:26PM	Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday? (Benzinga)
12:00PM	Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:56AM	Stocks to Watch Monday: CoreWeave, IonQ, USA Rare Earth, RevMed (The Wall Street Journal)
11:36AM	These Stocks Are Todays Movers: USA Rare Earth, CoreWeave, Micron, Intel, Newmont, IonQ, Sarepta, and More (Barrons.com)
11:23AM	Sarepta Stock Climbs 11% on Positive Three-Year Study Results for Elevidys (Barrons.com)
09:26AM	Sarepta Says Elevidys Slows Duchenne Progression After Three Years (Benzinga)
09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
08:53AM	Loading…
08:53AM	Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys (Barrons.com)
08:00AM	Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients (Business Wire)
06:46AM	Sarepta, battling slowing sales, claims Duchenne gene therapys impact grows with time (BioPharma Dive)
05:36AM	Stock Market Today: Dow Jones, S&P 500 Futures Slip As Investors Brace For Mega-Cap Earnings-Brand Engagement, Nucor In Focus (Benzinga)
Jan-23-26 04:05PM	Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy (Business Wire)
Jan-21-26 10:50PM	2 Beaten-Down Stocks That Could Sink Even More in 2026 (Motley Fool)
Jan-16-26 09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks) -6.54%
Jan-13-26 08:08AM	JPM26: Sarepta CEO touts avalanche of Elevidys data amid 2025 safety woes (Pharmaceutical Technology)
Jan-12-26 04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily) -11.29%
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:58AM	Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues (Business Wire)
Jan-05-26 08:30AM	Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-25 05:20PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-25 01:13PM	Sarepta Therapeutics, Inc. (SRPT): A Bull Case Theory (Insider Monkey)
07:00AM	Loading…
Dec-11-25 07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
Dec-03-25 11:30AM	Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? (Zacks) +6.69%
Dec-02-25 08:00AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Nov-25-25 02:17PM	Trump Media Stock and 11 More Tax-Loss Victims to Avoid Until 2026 (Barrons.com)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
12:07PM	Trump Media and 11 More Stocks to Avoid Until 2026 (Barrons.com)
08:57AM	Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne (Business Wire)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +6.90%
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks) -6.75%
Nov-15-25 09:35AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
Nov-14-25 03:14PM	FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths (Associated Press Finance) +5.56%
02:54PM	Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information (Business Wire)
Nov-06-25 05:43AM	Sarepta (SRPT) Soars 15% on Bullish Rating (Insider Monkey) -5.52%
Nov-05-25 10:21AM	Mizuho upgrades Sarepta on confidence in Elevidys uptake (Investing.com) +15.25%
03:31AM	Sarepta Stock Tumbles 34% After Earnings Report. Why Shares Crashed. (Barrons.com)
Nov-04-25 04:51PM	These Stocks Moved the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com) -33.74%
04:14PM	Sarepta Loses A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
02:39PM	These Stocks Are Moving the Most Today: Palantir, Uber, Sarepta, Tesla, Norwegian Cruise Line, Hertz, AMD, and More (Barrons.com)
01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
11:54AM	Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More (Investopedia)
11:11AM	Sarepta Therapeutics Stock Tumbles After Trial Data (Schaeffer's Research)
10:59AM	Pfizer & Novo boost Metsera bids, Hertz stock skyrockets (Yahoo Finance Video)
10:14AM	Sarepta Loses Almost A Third Of Its Value On Failed Tests, Gene Therapy Outlook (Investor's Business Daily)
09:58AM	Sarepta Stock Tumbles 35% After Earnings Report. Why Shares Are Crashing. (Barrons.com)
09:39AM	Stocks to Watch Tuesday: Palantir, Sarepta, Tesla (The Wall Street Journal)
09:30AM	Sarepta Therapeutics (SRPT) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:05AM	Sarepta Earnings Beat Expectations. Why the Stock Is Down 40%. (Barrons.com)
07:39AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:13AM	Two of Sareptas DMD drugs fail to meet primary endpoint in confirmatory trial (Clinical Trials Arena)
06:20AM	Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking. (Barrons.com)
05:57AM	Palantir stock slides after earnings, and other early market movers (MarketWatch)
05:31AM	These Stocks Are Moving the Most Today: Palantir, Sarepta, Amazon, AMD, Pfizer, and More (Barrons.com)
04:00AM	Sarepta Duchenne drugs come up short in confirmatory test (BioPharma Dive)
12:00AM	Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ... (GuruFocus.com)
Nov-03-25 06:26PM	Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success (MarketWatch)
05:20PM	Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:23PM	Sarepta Crashes After Two Muscular Dystrophy Drugs Fail Confirmatory Tests (Investor's Business Daily)
04:16PM	Sarepta Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE (Business Wire)
Oct-28-25 11:44AM	Beam Therapeutics Inc. (BEAM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-27-25 04:05PM	Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results (Business Wire)
Oct-21-25 06:46AM	Tradr to Launch Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF (PR Newswire)
Oct-03-25 02:14PM	Sarepta (SRPT) on Soars 15.7% on 5th Day Ahead of Clinical Trial Results (Insider Monkey)
08:30AM	Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2025 World Muscle Society Congress (Business Wire)
Oct-02-25 02:39PM	How to make money from tax-loss selling between now and the end of the year (MarketWatch) +15.68%
05:31AM	FDA leaders are acting political, says ex-agency chief counsel (Pharmaceutical Technology)
Sep-30-25 06:00PM	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-25 04:38AM	Street Calls of the Week (Investing.com)
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire)
Sep-05-25 09:30AM	2 Beaten-Down Stocks to Avoid Right Now (Motley Fool)
09:00AM	Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year (Business Wire)
Sep-03-25 07:27AM	Sarepta Therapeutics (SRPT) Fell Despite Reporting Good Results (Insider Monkey)
Aug-28-25 08:21AM	Cell and gene therapies on correction course but not sinking (Pharmaceutical Technology)
Aug-26-25 06:15PM	Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 (PR Newswire)
Aug-23-25 11:33AM	Credit Fuels the AI Boom and Fears of a Bubble (Bloomberg)
Aug-21-25 12:13PM	Walmart weighs on Dow, Sarepta debt restructuring (Yahoo Finance Video)
09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
07:00AM	Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 (Business Wire)
06:56AM	Sarepta pushes off debt payments in bid to regain financial footing (BioPharma Dive)
Aug-20-25 11:37PM	Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" (Insider Monkey)
11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com)
Aug-18-25 09:03AM	Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your Rights - Contact Levi & Korsinsky Before August 25, 2025 (Newsfile)
07:00AM	How the Moms and Dads of Patients Won Sareptas Drug a Reprieve (Bloomberg)
Aug-15-25 09:15AM	Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT (PR Newswire) +7.44%
Aug-14-25 09:00PM	Lightning Round: I don't have a positive outlook on Sarepta, says Jim Cramer (CNBC TV)
04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily)
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +8.51%

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nicaise Claude	Director	Jan 29 '26	Option Exercise	13.71	10,500	143,955	38,312	Jan 29 08:05 PM
BEHRENS M KATHLEEN	Director	Jan 27 '26	Option Exercise	13.71	10,500	143,955	203,976	Jan 29 08:04 PM
Estepan Ian Michael	Chief Operating Officer	Dec 16 '25	Sale	22.31	13,187	294,202	193,300	Dec 18 08:05 PM
IAN M ESTEPAN	Officer	Dec 16 '25	Proposed Sale	22.31	13,187	294,145		Dec 16 05:05 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Barry Richard	Director	May 16 '25	Option Exercise	32.63	12,350	402,981	2,966,667	May 19 07:32 AM
Barry Richard	Director	May 13 '25	Option Exercise	19.23	20,246	389,359	2,954,317	May 15 07:00 AM
Nicaise Claude	Director	Mar 12 '25	Option Exercise	25.18	9,746	245,404	30,303	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Sale	99.64	2,491	248,203	27,812	Mar 13 08:00 PM
Nicaise Claude	Director	Mar 12 '25	Proposed Sale	99.65	2,491	248,226		Mar 12 05:33 PM

Open in Screener

ALLO

Allogene Therapeutics Inc

Feb 13 • 04:00PM ET

1.80

+0.18 11.11 %

Healthcare • Biotechnology • USA • NASD

ALLO Allogene Therapeutics Inc daily Stock Chart

Peers: NTLA CRSP EDIT BEAM FDMT IOBT SGMO CLLS DTIL CYTK

| Held by: VTI IWM VXF IWN IBB SCHA VTWO PRFZ VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.98	Insider Own	31.45%	Shs Outstand	223.16M	Perf Week	6.51%
Market Cap	404.51M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-0.36%	Shs Float	154.05M	Perf Month	5.88%
Enterprise Value	237.46M	PEG	-	EPS next Q	-0.23	Inst Own	50.92%	Short Float	12.22%	Perf Quarter	46.34%
Income	-212.01M	P/S	-	EPS this Y	28.71%	Inst Trans	-9.41%	Short Ratio	4.49	Perf Half Y	68.22%
Sales	0.00M	P/B	1.27	EPS next Y	6.69%	ROA	-41.21%	Short Interest	18.82M	Perf YTD	31.39%
Book/sh	1.41	P/C	1.60	EPS next 5Y	14.79%	ROE	-54.43%	52W High	3.78 -52.38%	Perf Year	27.66%
Cash/sh	1.12	P/FCF	-	EPS past 3/5Y	0.45% 6.26%	ROIC	-54.02%	52W Low	0.86 108.79%	Perf 3Y	-74.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-94.22% -	Gross Margin	-	Volatility	8.15% 9.52%	Perf 5Y	-94.82%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	37.10%	Oper. Margin	-	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.19	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	58.36	Recom	1.47
Dividend Gr. 3/5Y	- -	Current Ratio	8.19	EPS Q/Q	41.18%	SMA20	7.98%	Beta	0.62	Target Price	7.38
Payout	-	Debt/Eq	0.27	Sales Q/Q	-	SMA50	16.13%	Rel Volume	1.12	Prev Close	1.62
Employees	229	LT Debt/Eq	0.24	Earnings	Nov 06 AMC	SMA200	37.08%	Avg Volume	4.19M	Price	1.80
IPO	Oct 11, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.00% -100.00%	Trades		Volume	4,706,410	Change	11.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Oct-10-25	Downgrade	JP Morgan	Neutral → Underweight
May-14-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Mar-14-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$5
Aug-08-24	Resumed	Oppenheimer	Outperform	$13 → $11
May-31-24	Initiated	Piper Sandler	Overweight	$11
Jan-05-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jan-05-24	Downgrade	Guggenheim	Buy → Neutral
Dec-08-23	Initiated	Citigroup	Buy	$7
Dec-08-23	Initiated	Citigroup	Buy
Jun-26-23	Resumed	Oppenheimer	Outperform	$28
Mar-21-23	Initiated	Bernstein	Mkt Perform	$6
Jan-24-23	Upgrade	JP Morgan	Neutral → Overweight	$20 → $11
Jan-06-23	Upgrade	Robert W. Baird	Neutral → Outperform	$12
Dec-12-22	Downgrade	BofA Securities	Buy → Underperform	$24 → $9
Aug-10-22	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-15-22	Upgrade	Goldman	Neutral → Buy	$9 → $32
Jun-03-22	Initiated	Robert W. Baird	Neutral	$11
Feb-28-22	Reiterated	B. Riley Securities	Buy	$30 → $21
Oct-20-21	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-11-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks)
Feb-05-26 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -9.44%
07:58AM	Rapid Innovation is Reshaping Oncology: Stocks in Focus (Zacks)
Jan-26-26 09:40AM	Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? (Zacks) -12.21%
Jan-09-26 09:40AM	Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year? (Zacks) +14.77%
08:30AM	Loading…
Jan-08-26 08:30AM	Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T (GlobeNewswire)
Dec-15-25 05:39PM	Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis (GlobeNewswire)
Nov-10-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-25 11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks) +12.38%
12:11AM	Allogene Therapeutics Inc (ALLO) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-06-25 04:26PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -5.41%
04:05PM	Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Nov-03-25 09:04AM	Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting (GlobeNewswire)
Oct-30-25 08:30AM	Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire)
Oct-14-25 11:24AM	TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals (Zacks)
01:06PM	Loading…
Oct-13-25 01:06PM	Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain (Zacks)
10:15AM	TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder (Zacks)
Oct-10-25 12:21PM	CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza (Zacks) -18.54%
10:27AM	OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data (Zacks)
Oct-08-25 11:18AM	KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure (Zacks) +8.89%
11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
Oct-07-25 11:56AM	MRK Expands Tulisokibart Program in Three New Inflammatory Diseases (Zacks)
Sep-16-25 12:54PM	Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update (Zacks)
Sep-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report? (Zacks)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
Sep-05-25 11:00AM	AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA (Zacks)
10:04AM	AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia (Zacks)
Aug-27-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conference (GlobeNewswire)
Aug-14-25 11:11AM	Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
03:15AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
04:12PM	Loading…
Aug-13-25 04:12PM	Allogene Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update (GlobeNewswire)
Aug-12-25 09:34AM	Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-06-25 08:30AM	Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -5.36%
Aug-01-25 08:30AM	Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma (GlobeNewswire) -12.20%
07:10AM	Regeneron cancer bispecific rejected again; Allogene discloses trial death (BioPharma Dive)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire) +16.90%
Jul-21-25 09:41AM	Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025 (Zacks) +5.60%
Jun-12-25 11:30AM	Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? (Zacks)
Jun-04-25 12:00PM	All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy (Zacks)
Jun-01-25 10:45AM	Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO (GlobeNewswire)
May-23-25 08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-22-25 05:17PM	Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel (GlobeNewswire)
May-20-25 09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks) +6.42%
May-16-25 06:36AM	Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive)
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks) +14.40%
09:43AM	Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays (GuruFocus.com)
09:35AM	Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks) -15.68%
10:46AM	Q1 2025 Allogene Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:00AM	EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line (Zacks)
06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:18AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 04:11PM	Allogene Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:42AM	Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
May-12-25 09:40AM	Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
09:20AM	RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up (Zacks)
May-09-25 08:26AM	Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-06-25 08:30AM	Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update (GlobeNewswire) -20.99%
Apr-23-25 10:12AM	Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-07-25 08:30AM	Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma (GlobeNewswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-14-25 03:00PM	Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... (GuruFocus.com)
Mar-13-25 04:11PM	Allogene Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) -8.25%
04:02PM	Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Mar-03-25 08:30AM	Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update (GlobeNewswire) -7.69%
Feb-26-25 08:30AM	Allogene Therapeutics Announces Participation in March Investor Conference (GlobeNewswire)
Feb-25-25 04:10PM	Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia (GlobeNewswire) -7.24%
Feb-13-25 04:30PM	Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology (GlobeNewswire) +44.68%
Feb-04-25 08:30AM	Allogene Therapeutics Announces Participation in February Investor Conferences (GlobeNewswire)
Jan-29-25 08:30AM	Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer (GlobeNewswire)
Jan-28-25 08:30AM	Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases (GlobeNewswire)
Dec-26-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Dec-16-24 08:30AM	Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +8.99%
Dec-12-24 08:30AM	Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman (GlobeNewswire) -5.61%
Nov-25-24 12:00PM	Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why (Zacks)
Nov-19-24 08:30AM	Allogene Therapeutics Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-18-24 08:30AM	Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence (GlobeNewswire) -5.29%
Nov-08-24 06:07AM	Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... (GuruFocus.com)
Nov-07-24 04:11PM	Allogene Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
10:00AM	Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS (GlobeNewswire)
Nov-06-24 07:31AM	Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +7.69%
Nov-05-24 09:10AM	Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Nov-04-24 08:30AM	Allogene Therapeutics Announces Participation in November Investor Conferences (GlobeNewswire) +10.29%
Oct-31-24 10:01AM	Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-30-24 08:30AM	Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update (GlobeNewswire) -5.71%
Oct-29-24 08:30AM	Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC) (GlobeNewswire)
Oct-22-24 04:05PM	Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors (GlobeNewswire)
Oct-03-24 07:19AM	Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now (Insider Monkey)
Sep-30-24 08:30AM	Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference (GlobeNewswire)
Sep-26-24 08:30AM	Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence (GlobeNewswire)
Sep-14-24 05:39PM	Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 11:31AM	Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-08-24 09:50AM	Allogene (ALLO) Posts Narrower Than Expected Loss in Q2 (Zacks)
08:30AM	Allogene Therapeutics Announces Participation in Upcoming Investor Conferences (GlobeNewswire)

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Feb 02 '26	Sale	1.73	7,549	13,060	210,172	Feb 04 05:20 PM
Chang David D	President and CEO	Feb 02 '26	Sale	1.80	95,269	171,484	5,185,862	Feb 04 05:18 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Feb 02 '26	Sale	1.76	24,001	42,242	1,252,795	Feb 04 05:16 PM
Douglas Earl Martin	SVP, General Counsel	Feb 02 '26	Sale	1.76	22,900	40,304	564,948	Feb 04 05:12 PM
Yoshiyama Annie	SVP, Finance	Feb 02 '26	Sale	1.72	4,167	7,167	130,322	Feb 04 05:09 PM
Roberts Zachary	EVP of R&D	Feb 02 '26	Sale	1.77	35,700	63,189	581,166	Feb 04 05:07 PM
EARL DOUGLAS	Officer	Feb 02 '26	Proposed Sale	1.76	22,900	40,215		Feb 02 05:17 PM
GEOFFREY M PARKER	Officer	Feb 02 '26	Proposed Sale	1.76	24,001	42,189		Feb 02 05:16 PM
ZACHARY J ROBERTS	Officer	Feb 02 '26	Proposed Sale	1.77	35,700	63,353		Feb 02 05:16 PM
ANNIE T YOSHIYAMA	Officer	Feb 02 '26	Proposed Sale	1.72	4,167	7,178		Feb 02 05:15 PM
DAVID CHANG	Officer	Feb 02 '26	Proposed Sale	1.80	243,976	438,522		Feb 02 04:51 PM
BENJAMIN M BENESKI	Officer	Feb 02 '26	Proposed Sale	1.73	16,823	29,052		Feb 02 04:49 PM
Roberts Zachary	EVP of R&D	Jan 21 '26	Sale	1.56	26,269	40,980	616,866	Jan 23 04:15 PM
Roberts Zachary	Officer	Jan 21 '26	Proposed Sale	1.56	26,269	40,929		Jan 21 07:53 PM
Kazam Joshua A	Director	Dec 18 '25	Option Exercise	0.00	47,700	0	350,763	Dec 22 06:57 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Nov 17 '25	Sale	1.22	786	959	217,721	Nov 19 04:09 PM
Beneski Benjamin Machinas	Officer	Nov 17 '25	Proposed Sale	1.22	786	959		Nov 17 07:14 PM
Parker Geoffrey M.	CHIEF FINANCIAL OFFICER	Oct 21 '25	Sale	1.26	36,744	46,169	1,276,796	Oct 23 06:20 PM
Parker Geoffrey M.	Officer	Oct 21 '25	Proposed Sale	1.26	36,744	46,169		Oct 21 08:52 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Sale	1.42	36,885	52,377	107,431	Jun 12 04:18 PM
MESSEMER DEBORAH M.	Director	Jun 10 '25	Proposed Sale	1.42	36,885	52,391		Jun 10 04:29 PM
Yoshiyama Annie	SVP, Finance	Apr 21 '25	Sale	1.41	9,601	13,537	130,663	Apr 23 05:28 PM
Yoshiyama Annie	Officer	Apr 21 '25	Proposed Sale	1.41	9,601	13,537		Apr 21 04:49 PM
Chang David D	President and CEO	Mar 14 '25	Sale	1.96	46,668	91,469	5,276,569	Mar 18 05:30 PM
Beneski Benjamin Machinas	SVP, Chief Technical Officer	Mar 14 '25	Sale	1.98	5,488	10,839	218,507	Mar 18 05:28 PM
Beneski Benjamin Machinas	Officer	Mar 14 '25	Proposed Sale	1.97	5,488	10,839		Mar 14 04:58 PM
Chang David D	Officer	Mar 14 '25	Proposed Sale	1.96	46,668	91,469		Mar 14 04:57 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Sale	2.43	13,313	32,351	144,316	Feb 20 04:15 PM
MESSEMER DEBORAH M.	Director	Feb 18 '25	Proposed Sale	2.43	13,313	32,329		Feb 18 05:27 PM

SRPT

Sarepta Therapeutics Inc

ALLO

Allogene Therapeutics Inc

Upgrade your FINVIZ experience